SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : LEXG-Lexicon Genetics
LXRX 1.390+3.7%Oct 31 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (129)12/18/2002 9:25:04 AM
From: tuck  Read Replies (2) of 254
 
>>THE WOODLANDS, Texas, Dec. 18 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today the formation of an alliance with Genentech, Inc. (NYSE: DNA - News) to discover new therapeutic proteins and antibody targets.

Under the terms of the three-year alliance, Lexicon will work to discover the physiological function and potential medical use of high-priority genes identified through Genentech's drug discovery research program. Genentech obtains certain exclusive and non-exclusive rights for the research, development and commercialization of therapeutic proteins and antibodies resulting from the collaboration. Separately, Lexicon granted Genentech an internal use sublicense under the patent covering its isogenic DNA gene targeting technology.

Lexicon will receive an upfront payment, performance based payments and a convertible loan that together could total up to $39 million if all such performance milestones are met. Under the terms of the agreement, Lexicon will be eligible to receive pre-commercialization product development milestone payments for each product incorporating or targeting an alliance protein for which Genentech obtains exclusive commercialization rights, and also will be entitled to receive royalties on net sales of all such products.

"Genentech has built an impressive intellectual property and product portfolio with respect to a large number of potential therapeutic proteins," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "We look forward to combining Genentech's portfolio with Lexicon's in vivo drug discovery capabilities."

A conference call will be held on Wednesday, December 18, 2002 at 10:00 a.m. EST. The webcast can be viewed at lexicon-genetics.com. It will be archived through December 27, 2002. Conference call participants may dial: 800/967-7137 (domestic), 719/457-2627 (international). A replay of the call will be available through December 27, 2002. Replay numbers: 888/203-1112 (domestic), 719/457-0820 (international). Pass code for all callers: 340908.<<

snip

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext